1. Bruton’s tyrosine kinase inhibitor pirtobrutinib showed efficacy in the treatment of relapsed or refractory B-cell malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom macroglobulinemia and marginal zone lymphoma.
2. Pirtobrutinib had a manageable safety profile, with few grade 3 or more adverse events.
Evidence Rating Level: 1 (Excellent)